SEC Company Response from ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525) (AZR) — Apr 28, 2020

ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525)
Date: April 28, 2020 · CIK: 0001513525 · Accession: 0001213900-20-010229

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-237793

Date

April 28, 2020

Author

William B. Stilley III

Form

CORRESP

Company

ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525)

Letter

1180 Seminole Trail, Suite 495

Charlottesville, VA 22902

(434) 422-9800

April 28, 2020

VIA EDGAR

United States Securities and Exchange Commission Division of Corporation Finance

100 F Street, N.E. Washington, D.C. 20549

Attention: Mr. Todd Schiffman

Re: Adial Pharmaceuticals, Inc.

Registration Statement on Form S-3

File No: 333-237793

Ladies and Gentlemen:

Adial Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the United States Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-237793), to become effective on Thursday, April 30, 2020, at 10:00 a.m., Eastern Time, or as soon thereafter as is practicable.

The Registrant hereby authorizes its counsel, Leslie Marlow, Esq. or Patrick J. Egan, Esq. of Gracin & Marlow, LLP, to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457 or Mr. Egan at (914) 557-5574 or (212) 907-6457 with any questions you may have concerning this request, and please notify her when this request for acceleration has been granted.

Very truly yours,
ADIAL PHARMACEUTICALS, INC.

Show Raw Text

CORRESP
1
filename1.htm

1180 Seminole Trail, Suite 495

Charlottesville, VA 22902

(434) 422-9800

April 28, 2020

VIA EDGAR

United States Securities and Exchange Commission
 Division of Corporation Finance

100 F Street, N.E.
 Washington, D.C. 20549

 Attention:
Mr. Todd Schiffman

    Re:
    Adial Pharmaceuticals, Inc.

                           Registration Statement on Form S-3

                           File No: 333-237793

Ladies and Gentlemen:

Adial Pharmaceuticals,
Inc. (the “Registrant”) hereby requests that the United States Securities and Exchange Commission (the “Commission”)
take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-237793), to become effective
on Thursday, April 30, 2020, at 10:00 a.m., Eastern Time, or as soon thereafter as is practicable.

The Registrant
hereby authorizes its counsel, Leslie Marlow, Esq. or Patrick J. Egan, Esq. of Gracin & Marlow, LLP, to orally modify or
withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457 or Mr. Egan at (914)
557-5574 or (212) 907-6457 with any questions you may have concerning this request, and please notify her when this request
for acceleration has been granted.

    Very truly yours,

    ADIAL PHARMACEUTICALS, INC.

    By:
    /s/ William B. Stilley III

    Name: William B. Stilley III
Title: Chief Executive Officer

    cc:
    Leslie Marlow, Esq., Gracin & Marlow, LLP

SecProbe.io